EU Approves Bavarian Nordic's Mpox Vaccine for Children Aged 2-12

Danish biotech company Bavarian Nordic has secured approval from the European Commission for its mpox/smallpox vaccine to be used in children aged 2 to less than 12 years. The decision, announced on August 7, extends the vaccine's existing authorization to a younger demographic, potentially broadening the pediatric response to mpox outbreaks across the European Union.

The approval marks a significant step in making the vaccine available to a vulnerable age group that has been affected by recent mpox cases. Bavarian Nordic's vaccine, already authorized for adults, will now be available for younger children, offering a preventive tool for families and healthcare providers.

This regulatory clearance comes amid ongoing efforts to control mpox transmission, particularly in regions where the virus has spread among children. The European Commission's decision is based on data demonstrating the vaccine's safety and efficacy in this age group, though specific trial details were not disclosed in the announcement.

Bavarian Nordic has not yet commented on rollout plans or supply timelines, but the approval positions the company to meet potential demand from EU member states seeking to protect younger populations. The vaccine's expanded indication could also influence public health strategies in other regions facing similar challenges.